"We acknowledge that the impact in the near term is likely to be limited given drug adoption will grow gradually over time, but we could see a longer-term impact as drug prevalence increases," Morgan Stanley's Paula Kaufman wrote in a note to clients. "Moreover, we expect companies to adapt to chang